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Abstract
Introduction. The aim of this study is to report the current status of ovarian
tissue cryopreservation among alternatives for fertility preservation in the Nor-
dic countries. Material and methods. A questionnaire was sent to 14 Nordic
academic reproductive centers with established fertility preservation programs.
It covered fertility preservation cases performed up to December 2014, stan-
dard procedures for ovarian tissue cryopreservation and oocyte cryopreserva-
tion and reproductive outcomes following ovarian tissue transplantation.
Results. Among the Nordic countries, Denmark and Norway practice ovarian
tissue cryopreservation as a clinical treatment (822 and 164 cases, respectively)
and their programs are centralized. In Sweden (457 cases), ovarian tissue cry-
opreservation is practiced at five of six centers and in Finland at all five centers
(145 cases). Nearly all considered ovarian tissue cryopreservation to be experi-
mental. In Iceland, embryo cryopreservation is the only option for fertility
preservation. Most centers use slow-freezing methods for ovarian tissue cryop-
reservation. Most patients selected for ovarian tissue cryopreservation were
newly diagnosed with cancer and the tissue was predominantly retrieved
laparoscopically by unilateral oophorectomy. Only minor complications were
reported. In total, 46 women have undergone ovarian tissue transplantation
aiming at recovering fertility, 17 healthy children have been born and several
additional pregnancies are currently ongoing. Whenever patients’ clinical con-
dition is permissive, oocyte cryopreservation after hormonal stimulation is pre-
ferred for fertility preservation. Between 2012 and 2014, a smaller proportion
of females have undergone fertility preservation in the Nordic centers, in com-
parison to males (1:3). Conclusions. Overall, ovarian tissue cryopreservation
was reported to be safe. Slow freezing methods are still preferred. Promising
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Introduction
Data from the Association of Nordic Cancer Registries
indicate that in the Nordic countries (Denmark, Finland,
Iceland, Norway and Sweden), approximately 145 000
individuals are diagnosed with cancer each year. About
10 000 of these are children, adolescents or young adults
of reproductive age (1). Fertility preservation has gained
increased acceptance in reproductive medicine and many
centers worldwide have established programs for this ser-
vice. Young individuals diagnosed with cancer are the
most representative patients with clear indications for fer-
tility preservation, owing to the recognized highly toxic
effects of chemotherapy and high-dose radiation on the
gonads and subsequent development of infertility as a
result (2). As improvements in cancer therapy are result-
ing in increasing numbers of long-term survivors, all
quality-of-life aspects, including the preservation of fertil-
ity, have become of major importance. International
guidelines for fertility preservation have been provided
(3,4) and these have had an impact on clinical practice in
the medical community. Hence the number of interna-
tional reports and publications, including preclinical, clin-
ical and epidemiological research on fertility preservation
for adults and children is constantly increasing (5).
For female patients, methods for fertility preservation
have been developed and are currently classified into clin-
ically established methods such as cryopreservation of
embryos and oocytes, whereas ovarian tissue cryopreser-
vation (OTC) is still considered experimental by interna-
tional collaborative work groups, such as those recently
organized by the American Society of Clinical Oncology
(4) in 2013 and by the American Society of Reproductive
Medicine (ASRM) (6) in 2014. In Europe, large series of
women who have undergone OTC have been reported
(7,8). When combining reported live births in these ser-
ies, 28 women of 80 who underwent ovarian tissue trans-
plantation in Belgium, Denmark, Germany and Spain, are
indicative of a promising 35% success rate with addi-
tional pregnancies ongoing (7–9). Worldwide, however,
the lack of an international register means that the num-
ber of transplantations performed is not known, as many
centers have not yet reported their results.
The aim of our study was to collect and report data
from the Nordic countries with regard to the develop-
ment of programs for fertility preservation for female
patients. We have focused on reporting activities in OTC
and transplantation procedures and also oocyte cryop-
reservation for fertility preservation. In all the Nordic
countries, standards of care include national health insur-
ance programs, which cover infertility investigation and
subsequent performance of assisted reproductive tech-
niques, with only modest differences in regulations
regarding access to such medical care across the coun-
tries. In the Nordic countries, OTC is currently restricted
to fertility preservation programs at academic reproduc-
tive centers that belong to large university hospitals. So
far, the only Nordic center that has reported reproductive
outcomes of their OTC program is the group from
Rigshospitalet University Hospital, Copenhagen, repre-
senting three clinics covering the entire Danish popula-
tion (9,10). In addition, a few centers have reported
successful single cases (11,12), but the overall activity in
the Nordic countries remains, until now, elusive and has
not been reported.
Material and methods
All Nordic university hospitals with established reproduc-
tive medicine centers that have initiated programs for fer-
tility preservation indicated by medical reasons and that
might practice OTC were identified for this survey
(n = 14). Thirteen of the reproductive medicine centers
belong to their university hospitals. The remaining center
(ART Medica, Reykjavik, Iceland) is a privately run clinic
associated with Landspitali University Hospital of Reyk-
javik, for teaching activities. Additional private reproduc-
tive centers that perform elective oocyte cryopreservation
were not considered. Clinicians responsible for fertility
preservation programs at the centers were requested to
respond to a questionnaire developed for this study (see
Appendix S1). The questionnaire, developed by K.R.W.,
Key Message
Ovarian tissue cryopreservation is practiced at most
Nordic Reproductive Medicine centers and it was
reported as safe and effective. Recovery of fertility by
ovarian tissue transplantation has been achieved in
several centers that have initiated transplantation pro-
cedures.
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T.T. and C.Y.A., concerned historical development of fer-
tility preservation programs including legal and technical
aspects, initiation of fertility preservation by OTC and
oocyte cryopreservation and cases performed until 31
December 2014, methodology used and changes over time
in addition to clinical characteristics of patients and stan-
dard procedures for OTC, complications, number of cases
of ovarian tissue transplantation performed, and repro-
ductive outcomes. The annual numbers of both female
and male fertility preservation cases at the centers during
the period 2012–2014 was also requested, to obtain a
clinical context and comparator to female fertility preser-
vation and OTC within the fertility preservation
programs.
Submitted data, with last entry 30 October 2015 were
primarily compiled by K.R.W. All 14 centers replied
(100% response). The procedures were in accordance
with the ethical standards of the responsible local or
national committee on human experimentation and with
the Helsinki Declaration of 1975, revised in 1983. Ethics
approval for the review of medical records and for these
analyses was granted by the Regional Ethics Committee
in Stockholm (Dnr 2011/1758-31/2 and Amendment
2014/1825-32) and by local ethics committees.
Results
Historical, technical and legal aspects
The Sahlgrenska University Hospital in Gothenburg pio-
neered OTC by offering it to three women aiming at fertil-
ity preservation in 1995; the women underwent this
procedure at their Department of Obstetrics and Gynecol-
ogy. The indication was potentially gonadotoxic treatment
of malignancy – one woman with breast cancer and two
with Hodgkin’s lymphoma. Tissue was cryopreserved
according to the method developed by Gosden et al., using
dimethylsulfoxide and sucrose as cryoprotectants and a
slow-freezing protocol (13). In 1999 OTC was initiated at
both Righshospitalet University Hospital in Copenhagen
and at Karolinska University Hospital in Stockholm. The
protocols established at these centers included slow-freez-
ing methods using ethylene glycol and sucrose (14), and
propanediol and sucrose (15), respectively. Table 1 shows
the methods that are currently practiced at each center.
Two centers have changed their methods for OTC over
time. Further research at the Karolinska Institute allowed
the development of vitrification methods for cryopreserva-
tion of ovarian tissue (16,17) and at Karolinska University
Hospital tissue retrieved for fertility preservation was cry-
opreserved by vitrification in 2009–2012. Today, half of
the ovarian tissue retrieved is cryopreserved by slow-freez-
ing and the remaining half by vitrification. Overall, the
slow-freezing methods are still preferred and practiced at
all centers. Vitrification of ovarian tissue was also tested
during a 2-year period at Tampere University Hospital
(2009–2011), but the group then continued with slow
freezing for OTC.
Two Nordic countries have national centralized pro-
grams established for OTC. In Denmark, a program was
established at Rigshospitalet, after approval by the Min-
istry of Health in Copenhagen and Frederiksberg (J/KF/
01/170/99). Similarly, in Norway, the Ministry of Health
and Care services centralized OTC activity to Oslo
University Hospital in 2004. In both countries, the per-
formance of OTC is approved as a clinical treatment.
In Finland and Sweden, fertility preservation programs
have been developed at university hospitals that provide
healthcare to large regions/counties. One center in Swe-
den still does not practice OTC. There is no established
agreement in the categorization of OTC as a clinical or
experimental option for fertility preservation (Table 1).
Regarding oocyte cryopreservation, the first Nordic
center to perform this procedure for fertility preservation
was the Center for Reproduction at Uppsala University
Hospital in 1994. Several centers included oocyte cryop-
reservation within their programs for fertility preservation
during the 1990s. Slow-freezing methods were performed
for about 13 years until the introduction of oocyte vitrifi-
cation at the clinics, which commenced in 2007. Cur-
rently, commercial and kit-based methods for vitrification
with closed systems are used at all centers.
Most centers prefer the option of oocyte cryopreserva-
tion for fertility preservation in adult women rather than
performing OTC, if time is available and the clinical con-
dition of the patient allows ovarian stimulation and
oocyte retrieval. In Iceland, the only method practiced for
fertility preservation is the freezing of embryos, however,
a partnership collaboration has been established with
Karolinska University Hospital in Stockholm for patients
interested in oocyte cryopreservation after hormonal
stimulation (Table 1).
All procedures for female fertility preservation are
reimbursed in agreement with national healthcare policies
at all centers.
Clinical characteristics of patients and standard
procedures for OTC
Patient characteristics and indications for OTC at the
centers performing this option for fertility preservation
are presented in Table 2. All centers have included adult
women, but restricted OTC to women younger than
40 years of age. Exceptionally, OTC procedures have been
offered to women above that age. Common indications
for adult women include breast cancer, Hodgkin’s disease,
ª 2016 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd
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lymphoma, sarcoma, and gynecological cancer. Several
centers have performed OTC for children, in most cases
indicated by malignancies (hematological cancer, sarcoma,
Hodgkin’s lymphoma, central nervous system malig-
nancy), but OTC has also been performed in some cen-
ters in connection with benign conditions such as Turner
syndrome.
Unilateral oophorectomy is performed in most centers
and none have reported any severe complications. Infec-
tion screening is routinely performed at all centers,
according to European standards recommended by the
European Union Tissues and Cells Directives.
Patients who have undergone oocyte
cryopreservation
In Table 3 the most common indications for fertility
preservation by oocyte cryopreservation are presented.
Although no absolute numbers according to diagnosis
were requested, nine out of 14 centers reported that
women with breast cancer are the largest patient group to
undergo these treatments, followed by women with hema-
tological malignancies (Table 3). Several centers have
included stimulation protocols adapted for breast cancer
in their fertility preservation programs (18,19).
Only rarely have women older than 40 years undergone
fertility preservation by oocyte cryopreservation at Nordic
clinics (Table 3). Most programs follow the age limits
recommended for assisted reproductive technology in
their countries as regards the performance of female fer-
tility preservation, i.e. fertility preservation procedures
can only be offered to women within the age limits for
national healthcare policy regulated and reimbursed
assisted reproductive technology, which in Sweden is up
to a female age of 40 years.
Ovarian tissue transplantation and clinical
outcomes
Table 4 presents a summary of ovarian tissue transplanta-
tion activities in the Nordic countries and the results
obtained among women who have requested transplanta-
tion of the tissue to recover fertility.
Several centers have initiated transplantation proce-
dures. In some cases, including seven women treated at
Rigshospitalet University Hospital and two women treated
at Karolinska University Hospital, the indication for reim-
plantation was aimed at the relief of climacteric symptoms.
In one girl treated at Rigshospitalet University Hospital,
the primary indication was puberty induction (20).
With regard to women with fertility wishes, the ovarian
tissue transplantation procedures have been successful
at several centers, with the greatest experience ofTa
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transplantation of frozen and thawed ovarian tissue at
Rigshospitalet in Copenhagen, where currently 14 children
have been born to women who regained fertility through
these procedures. Additionally, there are currently a few
ongoing pregnancies at the time of preparing this report.
Age limits for reimplantation of ovarian tissue have
been considered at most of the centers, and some centers
agree on the fact that the tissue should not be trans-
planted to postpone the natural menopausal age
(Table 4).
Fertility preservation for females and males
The number of young patients (both male and female)
that were referred for fertility preservation at the centers
during the last 3 years was also investigated. The data are
presented in Table 5. The numbers of both women and
men who undergo fertility preservation are increasing at
all centers, although the number of females who have
undergone fertility preservation is still small in compar-
ison with that of males who have banked frozen sperm,
approximately one in three.
Discussion
The focus of this survey was to collect and report data on
female fertility preservation activities through OTC and
ovarian transplantation procedures in the Nordic coun-
tries. Furthermore, data on additional fertility preserva-
tion options for females such as oocyte cryopreservation
Table 3. Oocyte cryopreservation for fertility preservation of females at 14 Nordic centers (total n = 455); current methods, date of initiation
and clinical characteristics of patients are presented.
Centers performing oocyte
cryopreservation for fertility
preservation
Year of start:
slow freezing/
vitrification
Method preferred, OTC vs.
oocyte cryopreservation
No. of cases
of oocyte
cryopreservation
Age
range Common indications
Denmark
Copenhagen Rigshospitalet
University Hospital
2006/2010 Both available 20 32–43 Breast cancer,a genetic
conditions, hematological
Finland
Helsinki University Hospital 2010/2012 Oocyte cryopreservation 12 18–38 Lymphoma, breast cancer
Kuopio University Hospital –/2012 Oocyte cryopreservation 5 13–30 Cancer, need of stem cell
transplantation
Oulu University Hospital 2009/2012 Oocyte cryopreservation 3 15–40 Hodgkin’s lymphoma,
hematological benign diseases
Tampere University Hospital 2007/2011 Both available 5 17–32 Lymphoma, breast cancer,
ovarian tumor
Turku University Hospital –/2012 Oocyte cryopreservation 5 22–32 Breast cancer,a benign
premature ovarian insufficiency
Iceland
Reykjavik Art Medica –/– Oocyte cryopreservation in
collaboration with Karolinska
Hospital since 2014
2 33–35 Breast cancera
Norway
Oslo University Hospital –/2014 OTC 0 – –
Sweden
Gothenburg Sahlgrenska
University Hospital
1995/2010 Oocyte cryopreservation if time
available
74 17–40 Breast cancer,a Hodgkin’s
lymphoma, cervical cancer
Link€oping, University
Hospital
2007/2013 Oocyte cryopreservation if time
available
28 16–35 Breast cancer,a other
malignancies, need of stem cell
transplantation
€Orebro, University Hospital 2006/2012 Oocyte cryopreservation 12 19–35 Breast cancer,a lymphoma, other
malignancies
Uppsala, University Hospital 1994/2008 Oocyte cryopreservation 42 17–38 Breast cancer,a need of stem cell
transplantation, other
malignancies
Malm€o Skane University
Hospital
–/2013 Both available 25 21–39 Breast cancera
Stockholm, Karolinska
University Hospital
1999/2007 Oocyte cryopreservation 222 15–42 Breast cancer,a hematological
malignancies
aAt nine of the 14 centers, breast cancer was reported as the most common cause for fertility preservation by oocyte cryopreservation.
ª 2016 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd
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were also requested, as well as the centers’ preferences as
regards to these methods. Our results indicate that OTC
has been practiced on a large scale and for many years at
certain Nordic centers. Most OTC procedures have been
carried out to preserve fertility in women and girls with
malignancies and to a minor degree have also been
offered to girls with benign conditions such as Turner
syndrome. Surgical retrieval of ovarian tissue is consid-
ered to be safe as self-reported by the centers; no major
complications were recorded, although it should be noted
in this context that there may be recall bias. Importantly,
our data are in agreement with results from several Euro-
pean groups that have reported OTC to be a safe activity
in female programs for fertility preservation (7,21,22).
The efficacy of ovarian tissue transplantation proce-
dures for regaining fertility is also proven in this study, as
the procedures have resulted in successful pregnancies
and healthy children, which even occurred at centers that
had only recently initiated transplantation of ovarian tis-
sue and that did not have any previous experience of this
type of surgery. Our findings are also in line with previ-
ous data (7–9), and are encouraging for suitable centers
that have not yet implemented this service with OTC and
reimplantation.
Most of the centers that do not have national central-
ized programs reported that they would prefer the option
of oocyte cryopreservation for female fertility preserva-
tion, rather than OTC, if a woman’s condition allowed
hormonal stimulation and time was available. An impor-
tant argument for this was that oocyte cryopreservation is
today considered as an established clinical option for fer-
tility preservation (4,23) and reproductive medicine spe-
cialists are familiar with the procedures. At such centers,
OTC came as a second option for adult women, or in
cases of unwanted hormonal stimulation or when there is
a lack of time. Notably, only a few pregnancies have been
reported in women with cancer based on vitrification of
mature oocytes (24). Hence, the efficacy of this approach
needs to be evaluated after actual clinical experience. The
OTC procedure is clearly preferred as a first-line proce-
dure for young girls and prepubertal patients at all cen-
ters, which is in line with international recommendations
(4,25).
Our finding of an increasing number of patients
referred for fertility preservation at all university-based
centers indicates that oncologists and other specialists
treating young people for malignant and chronic diseases
are increasingly becoming aware of the fertility concerns
of their patients when planning gonadotoxic treatments.
However, our data raise implications as regards to access
and performance of fertility preservation, which seems to
be more restricted for women than for men, as the num-
ber of women referred for fertility preservation at centersTa
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that receive referrals for both genders was very low in
comparison with the respective numbers for men.
This can to some extent be explained by the need of
invasive techniques and time required to recover oocytes
and ovarian tissue for female fertility preservation,
whereas male patients can immediately be planned for
banking of several sperm samples. Another aspect of the
gender difference is the long-term categorization of pro-
cedures for female fertility preservation as “experimental
methods.” The label “experimental” was only relatively
recently removed (2013) for the cryopreservation of
oocytes by the American Society of Reproductive Medi-
cine (23) but it still remains with regard to OTC for fer-
tility preservation, which is obviously an additional
barrier for many female patients. The data collected here
from academic reproductive medicine clinics in Nordic
countries is in line with previous research findings of gen-
der differences in access to and performance of fertility
preservation in Sweden (26,27), irrespective of the fact
that the procedures for fertility preservation are reim-
bursed for all patients.
The performance of OTC for women aimed at fertility
preservation in Gothenburg, Sweden, as early as 1995, is
particularly noteworthy, because these patients were
perhaps the first ones in Europe to undergo this procedure.
To the best of our knowledge, centers that have reported
early experiences with OTC within fertility preservation
programs include the Catholic University of Louvain in
Belgium, which was granted approval for OTC in 1995
(28); the Groupe Hospitalier Pitie-Salpetriere in Paris,
which initiated OTC for adult women in 1998 and for pre-
pubertal girls in 2000 (29); and the Free University of Brus-
sels, which initiated OTC in 1999 (30). Similar to the group
of Sahlgrenska Hospital in Gothenburg, all these three cen-
ters also initiated their OTC programs using the slow-freez-
ing protocol developed by Gosden et al. (13).
In conclusion, fertility preservation is gaining ground
as an integral and important part of cancer treatment in
most Nordic hospitals, for both women and men. Den-
mark and Norway have national centralized programs for
OTC and in Sweden and Finland the regional programs
together cover the whole population. However, not all
patients are counseled before potentially gonadotoxic
treatment and national differences are evident. Further
investigation is needed to identify causes of gender differ-
ences in healthcare provision. The solid foundation of
fertility preservation services in the public healthcare sys-
tem, which provides free-of-charge care for eligible
Table 5. The number of patients referred for fertility preservation is increasing at all centers; in most centers, the number of males is several
times higher than the number of females.
Centers performing fertility preservation
for female and male patients
Females; cases of fertility
preservation last three
consecutive years (n)
Males; cases of fertility preservation last
three consecutive years (n)
2012 2013 2014 2012 2013 2014
Denmark
Copenhagen Rigshospitalet University Hospital 67 65 73 Not centralizeda
Finland
Kuopio University Hospital 3 5 3 15 10 11
Oulu University Hospital – 32 23 33
Helsinki University Hospital 5 7 10 50 60 70
Tampere University Hospital 8 6 7 25 38 22
Turku University Hospital 3 0 3 14 36 23
Iceland
Reykjavik ART Medica 2 2 2 7 6 14
Norway
Oslo University Hospital 20 13 19 176 156 154
Sweden
Gothenburg Sahlgrenska University Hospital 9 26 33 77 79 100
Link€oping University Hospital 3 7 11 40 50 60
€Orebro University Hospital 4 6 4 15 19 26
Uppsala University Hospital 21 22 17 81 74 76
Malm€o Skane University Hospital 15 20 22 82 89 100
Stockholm Karolinska University Hospital 125 109 116 125 160 162
Total cases 285 288 321 739 800 871
Data shown include patients referred per year for fertility preservation at the Nordic centres between 2012 and 2014.
aIn Denmark, freezing and banking of sperm is not centralized at Rigshospitalet University Hospital and is available at many centres.
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patients, has paved the way for increased implementation
of fertility preservation services during the coming years.
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